ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jan 21, 2014
Johnson & Johnson Registers Strong Fourth Quarter Performance; 2014 Outlook Conservative
We continue to like J&J’s fortress balance sheet and strong dividend growth potential.
Jan 8, 2014
The Best Ideas for 2014 and Beyond: Part II
Let’s dive into Part II of this special best ideas edition. This article focuses on the positions in the Dividend Growth portfolio.
Dec 23, 2013
Three Reasons Why Dividend Growth Investors Are Quite Savvy
Let's examine today's dividend growth investor.
Oct 20, 2013
Third-Quarter Industrial Earnings Support Exposure in Best Ideas Portfolio
A number of industrial firms’ calendar third-quarter earnings are out. Let’s take a look at how our Best Ideas portfolio is well-positioned to capture the strength of underlying trends.
Oct 15, 2013
Johnson & Johnson Remains One of Our Favorite Dividend Growth Gems
Johnson & Johnson issued strong third-quarter results and raised its full-year earnings guidance. We remain huge fans of this dividend growth gem.
Sep 26, 2013
MAKO Receives a Tremendous Offer from Stryker; Is Intuitive Surgical Next?
MAKO receives an offer from Stryker that was an 83% premium to its previous day's closing price. Let’s take a look at the deal and what it may mean for Intuitive Surgical.
Aug 5, 2013
Which Sectors Are Leading the Market Higher? And Why Is This Important?
Identifying sector and industry leadership is very important for the institutional money manager as doing so often leads to undervalued firms that are just starting to have their value recognized by the market — Valuentum stocks. Let’s dig into which sectors have been strong and which ones have been weak so far in 2013.
Jul 17, 2013
Strong Second Quarter Results at Johnson & Johnson
Johnson & Johnson exceeded second quarter expectations despite currency headwinds.
Jun 20, 2013
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Big Pharma is not dead, but neither are the generics. Let’s take a look at opportunities presented from patent expiry in the US and low generic utilization rates across the globe. We don’t think investors are expecting the “mountain” of opportunities in 2015.
Jun 4, 2013
ASCO Reveals That Big Pharma Is Alive
Some good news from Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Amgen showed the promise of immunotherapies for cancer treatment.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.